Corcept Therapeutics Incorporated
$ 90.52
0.89%
17 Jul - close price
- Market Cap 9,631,585,000 USD
- Current Price $ 90.52
- High / Low $ 91.45 / 87.22
- Stock P/E 256.34
- Book Value 5.94
- EPS 0.35
- Next Earning Report 2026-07-30
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.01 %
- ROE 0.07 %
- 52 Week High 95.11
- 52 Week Low 28.66
About
Corcept Therapeutics Incorporated discovers, develops, and markets drugs for the treatment of severe metabolic, cancer, and psychiatric disorders in the United States. The company is headquartered in Menlo Park, California.
Analyst Target Price
$97.50
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-30 | 2026-02-24 | 2025-11-04 | 2025-07-31 | 2025-05-05 | 2025-02-26 | 2024-10-30 | 2024-07-29 | 2024-05-01 | 2024-02-15 | 2023-11-01 | 2023-08-02 |
| Reported EPS | -0.3 | 0.2 | 0.16 | 0.29 | 0.17 | 0.26 | 0.41 | 0.32 | 0.25 | 0.28 | 0.28 | 0.25 |
| Estimated EPS | -0.14 | 0.254 | 0.14 | 0.19 | 0.14 | 0.4233 | 0.29 | 0.24 | 0.22 | 0.26 | 0.23 | 0.15 |
| Surprise | -0.16 | -0.054 | 0.02 | 0.1 | 0.03 | -0.1633 | 0.12 | 0.08 | 0.03 | 0.02 | 0.05 | 0.1 |
| Surprise Percentage | -114.2857% | -21.2598% | 14.2857% | 52.6316% | 21.4286% | -38.5778% | 41.3793% | 33.3333% | 13.6364% | 7.6923% | 21.7391% | 66.6667% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-07-30 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.04 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CORT
2026-07-09 17:40:43
This article provides an overview of Corcept Therapeutics (CORT), a biopharmaceutical company focused on treating severe disorders, including Cushing's syndrome with its flagship product Korlym. It highlights the company's robust pipeline, currently in late-stage clinical trials for various conditions. The article also lists recent related news, including an analysis of Crinetics Stock's soar and a comparison of Corcept Therapeutics with Amicus Therapeutics.
2026-07-09 13:40:43
Corcept Therapeutics (CORT) was removed from the Russell 1000 Growth Defensive Index and the Russell 1000 Defensive Index, which primarily impacts trading activity and liquidity. The stock has seen significant share price momentum over the past year, with a 31.1% one-year total shareholder return. Despite this, Corcept is currently trading slightly above its fair value estimate of $88, suggesting it might be overvalued, and still faces risks such as patent litigation.
2026-07-09 00:44:49
Corcept Therapeutics' Chief Business Officer, Gary Charles Robb, reported a gift of 600 shares of common stock on May 27, 2026, with no sale price. Following this transaction, Robb directly holds 25,081 shares, and indirectly holds 49,716 shares through a revocable trust and 12,571 shares in each of two custodial accounts for children. The filing also details several unvested restricted stock awards that will vest on their one-year anniversary dates, subject to service conditions.
2026-07-08 23:41:49
Corcept Therapeutics' Chief Development Officer, William Guyer, sold 20,000 shares of company stock for approximately $1.86 million, executed under a pre-arranged trading plan. This sale occurred near the stock's 52-week high, with the company also having other recent developments including a resubmitted New Drug Application and positive Phase 3 trial data for relacorilant. Despite these developments and a reiterated "Buy" rating from H.C. Wainwright, InvestingPro analysis suggests the stock may be overvalued.
2026-07-08 23:41:49
Corcept Therapeutics Chief Development Officer William Guyer exercised stock options for 20,000 shares at $21.65 and simultaneously sold them on the open market at weighted average prices of $93.11 and $93.54. These transactions, totaling $1.86 million, were conducted under a pre-arranged Rule 10b5-1 trading plan adopted in November 2024. Following these sales, Guyer retains 4,937 common shares, 130,000 stock options, and unvested restricted stock awards, indicating a planned liquidity event with continued equity interest.
2026-07-08 23:41:49
This article from Investing.com announces a Form 4 filing for Corcept Therapeutics Incorporated (CORT) on July 8. The brief update provides the stock symbol and its recent performance (-1.17%), indicating a transactional report relevant to the company. The rest of the content includes market data, trending stocks, and advertisements commonly found on financial news platforms.
